Orano Med SASU

https://www.oranomed.com

Orano Med is a clinical-stage biotechnology company which develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emitter Therapy (TAT). Alpha decay results in irreparable double strand DNA breaks in cells adjacent only to area of alpha emission, which leads to an increased cytotoxic potential toward cancer cells while limiting toxicity to nearby healthy cells. As a result, alpha emitters are considered as the most powerful payloads to be found for targeted therapies. Orano Med develops several treatments using 212Pb combined with various targeting agents. The company has 212Pb manufacturing facilities, laboratories, and R&D centers in France and in the US and is currently investing to further expand its GMP-manufacturing capacities for 212Pb radiolabeled pharmaceuticals in North America and Europe. *

	Start	2018-01-23 renamed
	Group	Orano (Group)
	Predecessor	Areva Med (FR)
	Industry	MedTech (medical technology)
	Industry 2	Lead-212 (212Pb) Targeted Alpha Therapy

	Street	125 avenue de Paris
	City	92320 Chatillon
		Address record changed: 2023-09-11

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2025-03-16

Picture Berlin Partner Voices Surjo Soekadar 650x200px

More documents for Orano (Group)

[1] Orbit Discovery Ltd.. (9/11/23). "Press Release: Orano Med and Orbit Discovery Enter Collaboration to Discover Novel Targeted Radioligand Therapies for Cancer". Texas & Oxford....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)